The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression

  • 0Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

|

|

Summary

This summary is machine-generated.

Enoyl-CoA δ-isomerase 2 (ECI2) suppresses colorectal cancer (CRC) by inhibiting ether lipid production, reducing neutrophil recruitment and extracellular trap formation. ECI2 acts as a tumor suppressor, offering potential diagnostic and therapeutic targets for CRC.

Area Of Science

  • Biochemistry
  • Oncology
  • Immunology

Background

  • Ether lipid metabolism and neutrophil extracellular traps (NETs) are implicated in cancer progression.
  • The specific role of aberrant ether lipid metabolism in colorectal cancer (CRC) evolution remains unclear.

Purpose Of The Study

  • To investigate the function of the lipid metabolism-related gene enoyl-CoA δ-isomerase 2 (ECI2) in colorectal cancer.
  • To elucidate the molecular mechanisms by which ECI2 influences CRC progression and prognosis.

Main Methods

  • Analysis of ECI2 expression in CRC patient data.
  • Mechanistic studies involving ECI2, ether lipid metabolism, Interleukin 8 (IL-8) expression, and neutrophil activity.
  • Investigation of ECI2's effect on the peroxisomal localization of alkylglycerone phosphate synthase (AGPS).

Main Results

  • ECI2 exhibits a tumor-suppressor role in CRC and is associated with improved patient prognosis.
  • ECI2 reduces ether lipid-mediated IL-8 expression, thereby decreasing neutrophil recruitment and NET formation.
  • ECI2 inhibits ether lipid synthesis by preventing the peroxisomal localization of AGPS, the key enzyme in ether lipid production.

Conclusions

  • ECI2 functions as a tumor suppressor in colorectal cancer by modulating ether lipid metabolism and neutrophil responses.
  • These findings enhance understanding of metabolic reprogramming and immune cell interactions in CRC.
  • ECI2 represents a potential diagnostic marker and therapeutic target for colorectal cancer.